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Abstract: Background: Cardio-vascular target organ damage predicts the onset of type 2 diabetes
mellitus (DM) in hypertensive patients. Whether an increased incidence of DM is also in relation to
the severity of coronary atherosclerosis is unknown. Objective: We evaluated the onset of DM in
relation to the extent and severity of coronary atherosclerosis, using the SYNTAX (Synergy between
Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score (SS), in patients with
stable angina or acute coronary syndromes, referred for coronary angiography (CA). Methods:
Non-diabetic patients that underwent CA for the first time were included, and the SS was computed.
Predictors of DM onset in low, medium, and high SSs were investigated. Results: Five hundred
and seventy patients were included, and the mean SS was 6.3 ± 7.6. During a median follow-up
of 79 months (interquartile range (IQR): 67–94), 74 patients (13%) developed DM. The risk of DM
onset was significantly higher in the patients with a medium or high SS (hazard ratio (HR)—95%
confidence interval (CI): 16 (4–61), p < 0.0001; and 30 (9–105), p < 0.0001, vs low SS, respectively), even
after adjustment for obesity, history of hypertension, impaired fasting glucose, and cardiovascular
therapy. Conclusions: The severity and extent of the coronary atherosclerosis, evaluated by the SS, is
a strong and independent predictor of the development of DM in patients, referred to CA.
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1. Introduction
Type 2 diabetes mellitus (DM) and cardiovascular (CV) disease are closely correlated. DM is
associated with a two- to four-fold increased risk of coronary artery disease (CAD) and stroke [1].
On the other hand, CV diseases are the main causes of death and disability among patients with
DM [2]. Furthermore, DM is associated with more extensive coronary atherosclerosis [3], and worse
outcomes in acute coronary syndromes [4]. The association with coronary atherosclerosis spans from
early stages of glucose intolerance to overt DM [5–7]. We previously demonstrated, in hypertensive
patients, that uncontrolled blood pressure is associated with a two-fold increased risk of diabetes
onset [8]. In addition, hypertension-mediated target organ damage (e.g., carotid atherosclerosis and left
ventricular hypertrophy) is a significant predictor of DM onset, independently of the baseline metabolic
profile, anti-hypertensive therapy, and other significant covariates [9]. Thus, a well-characterized
phenotype of hypertensive patients, carrying features suggestive of a high atherosclerotic burden,
places patients at a higher risk for developing DM during follow-up. However, at this time, there is no
direct demonstration that atherosclerosis exposes patients to a higher risk of DM development with a
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dose-response pattern. Identifying patients with an increased risk of DM, in the setting of patients
referred to Cat Labs for coronary angiography (CA), might be of paramount importance in terms
of cardiovascular prevention [10]. Therefore, the early identification of individuals with established
coronary artery disease at risk of type 2 DM could be further assessed for the severity of atherosclerosis,
even before the clinical appearance of the disease, in order to promote the aggressive management of
the metabolic profile in these patients.
Accordingly, we investigated whether the extension and severity of CAD diagnosed during CA
might be predictive of the future onset of DM.
2. Research Design and Methods
2.1. Patients
We screened all of the consecutive patients who underwent CA at the Cardiovascular Center
Aalst (Belgium), between 1 January 2009 and 31 December 2009. The exclusion criteria were as follows:
previous coronary angiogram, history of myocardial infarction or coronary artery bypass graft, or
the diagnosis of pre-existing diabetes. All patients signed informed consent for CA and for data
collection before the procedure. During the index hospital admission for CA, the blood pressure
(BP), heart rate (HR), body mass index (BMI), fasting glucose, glycated hemoglobin (HbA1c), lipid
profile, and kidney function were routinely assessed for each patient. All of the patients underwent
trans-thoracic echocardiogram (TTE), analyzed oﬄine by one expert reader under the supervision
of a senior consultant, using dedicated work-stations (Echo-PAC Clinical Workstation Software, GE
Healthcare, Horten, Norway).
The SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac
Surgery) score (SS) was calculated for all of the patients by two interventional cardiologists blinded
to the baseline clinical characteristics, procedural data, and clinical outcomes. Each coronary lesion
with more than a 50% diameter stenosis in vessels of at least 1.5 mm, by visual estimation, was
scored separately using the SS algorithm from the related website [11]. To assess the intra-observer
reproducibility, angiograms were re-analyzed by the same interventional cardiologist eight weeks
after the first analysis. The investigator remained blinded to the results of the first analysis. After the first
admission for CA (index procedure), patients were assessed for incidence of type 2 diabetes in all of the
subsequent follow-up visits or laboratory exams at the Cardiovascular Center of Aalst. To standardize the
follow-up (FU), we analyzed the ambulatory visits and laboratory data every 6 months, until the last FU.
2.2. Primary Endpoint
The primary endpoint of the study was the incidence of type 2 DM after index hospitalization.
Diabetes was defined according to the 2018 American Diabetes Association (ADA) criteria, as follows:
fasting plasma glucose of 126 mg/dL (7.0 m mol/L) or hemoglobin A1C of 6.5% (48 mmol/mol) [12]. To
accurately date the first diagnosis of diabetes, we carefully checked on the initiation of anti-diabetic
therapies, and on the laboratory data at the occasion of the outpatient clinic visit. The onset of diabetes
was adjudicated based on the earliest evidence of ADA criteria at the follow-up.
2.3. Measurements and Definitions
Obesity was defined as a BMI of 30 kg/m2. According to the ADA criteria, impaired fasting
glucose (IFG) was considered when the fasting plasma glucose was between 101 and 125 mg/dL. The
systolic and diastolic blood pressure (BP) was measured by standard aneroid sphygmomanometer
after 5 min rest in the supine position. Three BP measurements were obtained in the sitting position,
at 2 min intervals. The averages of these measurements were used for the analysis. Hypertension is
defined as office systolic blood pressure (SBP) values of 140 mmHg, and/or diastolic BP (DBP) values
of 90 mmHg, according to the European Society of Cardiology (ESC) guidelines [13]. We defined
peripheral vascular disease (PVD) as disease documented by a vascular imaging study (including
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a Computed tomography (CT) scan, ultrasound, peripheral angiography, and magnetic resonance
imaging (MRI) that was significant enough for the patient to be referred for elective vascular surgery
or percutaneous intervention.
2.4. Statistical Analysis
The data were analyzed using IBM SPSS Statistics (version 25.0; SPSS, IBM, Armonk, NY, US),
and expressed as mean ± 1 standard deviation (SD). The variables that were not normally distributed
were log-transformed. The study population was divided into quartiles of SS. For the exploratory
statistics, we considered the two lowest quartiles as low-risk SS (group 1); the third one, corresponding
to the median of distribution, as moderate-risk SS (group 2); and the highest one, corresponding to
the 75th percentile of the distribution, as high-risk SS (group 3). Analysis of variance (ANOVA) was
used to compare the baseline characteristics of the three groups of patients according to SS. Under
the assumption of increasing abnormalities from group 1 to group 3, polynomial linear and quadratic
contrasts were used to estimate the trend. The χ2 distribution was used to compare the categorical
variables, with the Monte Carlo simulation in order to obtain exact p-values.
The incidence of diabetes in relation to the three groups of SS was assessed using three models
of Cox regression analysis, as follows: (a) in the first model, age, gender, and metabolic profile were
included; (b) in the second model, the echo parameters and classes of drugs were included; (c) in the
third model, the dosages (low vs high dosages) of the statins (i.e., patients on rosuvastatine ≥20 mg/die
or atorvastatine ≥40 mg/die were considered as high dosage) were included. A two-tailed p-value of
<0.05 was used to reject the null hypothesis.
3. Results
3.1. Patients
Within the study period, 570 non-diabetic (mean age 65 ± 10 years; 69% males) patients fulfilled
the inclusion and exclusion criteria, and were included in this analysis. Table 1 shows the demographic
and clinical characteristics of the patients stratified by SS. In the patient population, the included SSs
were as follows: SS low, 0 to ≤4; SS medium, >4 to ≤10; and SS high, >10. The patients in the high
SS were older, and showed a lower heart rate and left ventricular ejection fraction. The basal fasting
plasma glucose was found to be progressively higher among the patients with medium and high SS,
while the lipid profile was more favorable in the medium SS. Table 2 shows the medical therapy at
discharge from the index hospitalization. All four classes of medications considered in the analysis
were prescribed more frequently in patients with a higher SS.
Table 1. Baseline demographic and clinical characteristics of participants stratified by SYNTAX score (SS).
Low SS
(n = 295)
Medium SS
(n = 151)
High SS
(n = 124)
p
(for trend)
Age (years) 65.5 ± 10.4 63.9 ± 10.5 67.1 ± 10.3 0.045
Sex (male/female %) 68.8/31.2 72.8/27.2 74.2/25.8 NS
Smokers (%) 47.5 53.0 48.4 NS
Hypertensives (%) 67.5 76.8 75.8 NS
BMI (Kg/m2) 27.1 ± 4.5 27.2 ± 4.3 27.3 ± 5.4 NS
Systolic BP (mmHg) 133.3 ± 22.0 128.8 ± 17.1 133.2 ± 19.4 NS
Diastolic BP (mmHg) 69.5 ± 11.4 69.3 ± 10.6 69.3 ± 11.3 NS
HR (bpm) 67.7 ± 12.2 66.9 ± 11.9 64.6 ± 8.7 0.048
Ejection Fraction (%) 67.9 ± 16.0 64.9 ± 14.0 61.6 ± 15.4 0.001
Fasting plasma glucose (mg/dL) 83.8 ± 13.2 85.6 ± 13.4 94.7 ± 13.5 0.0001
HbA1c (mmol/mol) 40.5 ± 8.7 40.4 ± 7.3 41.0 ± 7.5 NS
Total cholesterol (mg/dL) 172.6 ± 44.2 154.4 ± 36.6 156.0 ± 41.6 0.0001
LDL cholesterol (mg/dL) 91.8 ± 39.0 77.8 ± 31.4 81.1 ± 34.7 0.001
HDL cholesterol (mg/dL) 52.2 ± 16.8 51.0 ± 17.9 46.4 ± 14.5 0.01
Triacylglycerols (mg/dL) 147.3 ± 83.0 124.4 ± 67.4 146.1 ± 87.2 0.044
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Table 1. Cont.
Low SS
(n = 295)
Medium SS
(n = 151)
High SS
(n = 124)
p
(for trend)
GFREPI (mL/min/1.73 m2) 64.7 ± 28.3 70.5 ± 25.6 64.3 ± 24.8 NS
CRP (mg/L) 27.7 ± 77.1 15.9 ± 34.0 28.7 ± 67.5 NS
IFG (%) 12.5 15.2 36.3 0.0001
BMI = body mass index; BP = blood pressure; HR = heart rate; HbA1C = hemoglobin glycated A1C; LDL = low
density lipoprotein; HDL = high density lipoprotein; GFR = glomerular filtration rate; CRP = C-reactive protein;
IFG = impaired fasting glucose; NS = not significant.
Table 2. Classes of drugs prescribed at the discharge.
Low SS
(n = 295)
Medium SS
(n = 151)
High SS
(n = 124) p
CCB (%) 2.7 8.6 14.5 <0.0001
β-blockers (%) 20.0 37.7 42.7 <0.0001
Statins (%) 39.0 76.8 83.9 <0.0001
Statins low dose (%) 32.5 58.3 64.5 <0.0001
Statins high dose (%) 6.5 18.5 19.4 <0.0001
Anti-RAS (%) 29.5 27.2 46.8 0.001
SS = SYNTAX score; CCB = calcium channel blockers; RAS = renin angiotensin system.
3.2. Follow-Up
During a median follow-up of 79 months (interquartile range (IQR): 67–94), 74 (13%) patients
developed DM. The incidence of diabetes was significantly higher in the patients with a high SS (41%),
than in patients with a medium (12%) and low SS (2%; p for trend < 0.0001; Figure 1). In the Cox
regression analysis (Table 3), the predictors of DM onset during follow-up had higher baseline values
of fasting plasma glucose (HR = 1.043; (95% CI 1.011–1.075); p < 0.008), medium SS (HR = 6.630; (95%
CI 2.394–18.358); p < 0.0001), and high SS (HR = 14.789; (95% CI 5.796–37.737); p < 0.0001). The three
curves (Figure 2) started to separate after 48–52 months from the index hospitalization, and further
diverged after five years of follow-up. In the second Cox regression analysis performed by including
the ejection fraction, heart rate, and the drugs prescribed (Table 4), the predictors of the new onset
of DM were as follows: use of statins (HR = 6.953; (95% CI 1.618–29.880); p = 0.009), an anti-renin
angiotensin system (RAS; HR = 3.338; (95% CI 1.917–5.812); p = 0.0001), medium SS (HR = 6.022; (95%
CI 1.714–21.158); p = 0.005), and high SS (HR = 13.140; (95% CI 3.857–44.738); p < 0.0001) was further
reinforced (Table 4). In the last model (Table 5), including the dosage of statins, the independent
predictors of DM were a low dose of statins (HR = 8.631; (95% CI 2.017–36.931); p = 0.004), a high dose
of statins (HR = 8.158; (95% CI 1.764–37.728); p = 0.007), anti-RAS (HR = 3.637; (95% CI 2.151–6.6.151);
p < 0.0001), medium SS (HR = 3.505; (95% CI 1.274–9.644); p = 0.015), and high SS (HR = 8.906; (95% CI
3.404–23.296); p = 0.0001).
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Figure 1. Rate of type 2 diabetes mellitus (DM) in the three SYNTAX score (SS) levels.
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Table 3. Results of Cox regression, including the age, gender, and metabolic profile.
Predictors Sig. HR
95.0% CI
Lower Upper
Sex (1 male/2 female) 0.583 1.163 0.679 1.993
Age (years) 0.085 1.026 0.996 1.056
Fasting plasma glucose (mg/dL) 0.008 1.043 1.011 1.075
LDL Cholesterol (mg/dL) 0.323 1.130 0.535 2.385
IFG (y) 0.749 7.865 2.817 21.959
Medium SS 0.000 6.630 2.304 18.358
High SS 0.000 14.789 5.796 37.737
Abbreviations as in Table 1. CI = confidence interval.
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Table 4. Results of Cox regression including ejection fraction, heart rate, and classes of drugs.
Predictors Sig HR
95.0% CI
Lower Upper
Ejection Fraction (%) 0.698 0.996 0.978 1.015
HR (bpm) 0.128 1.021 0.994 1.048
CCB (y) 0.549 0.215 0.643 2.296
B-blockers (y) 0.416 1.223 0.753 1.986
Statins (y) 0.009 6.953 1.618 29.880
Anti RAS (y) 0.000 3.338 1.917 5.812
Medium SS 0.005 6.022 1.714 21.158
High SS 0.000 13.140 3.857 44.768
Abbreviations as in Tables 1 and 2.
In patients who developed DM, no significant differences were detected in the incidence of major
adverse cardiovascular events (i.e., death, myocardial infarction, or coronary revascularization) among
the three SS subgroups (p = 0.418).
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Table 5. Results of the COX regression, including the classes of drugs and statins dosage.
Predictors Sig HR
95.0% CI
Lower Upper
CCB (y) 0.387 1.314 0.708 2.440
B-blockers (y) 0.390 1.238 0.761 2.013
Statins low dose (y) 0.004 8.631 2.017 36.931
Statins high dose (y) 0.007 8.158 1.764 37.728
Anti RAS (y) 0.0001 3.637 2.151 6.151
Medium SS 0.015 3.505 1.274 9.644
High SS 0.0001 8.906 3.404 23.296
Abbreviations as in Tables 1 and 2.
4. Discussion
In non-diabetic patients, our study demonstrates, for the first time, a significant association
between the severity and extent of coronary atherosclerosis, assessed by the SS, with the future
development of type 2 DM. Compared with patients with low SS, those with medium or high values
exhibited an 8-fold and 10-fold higher risk for developing type 2 DM during follow-up, an association
that was independent of potential confounders, including initial metabolic profile, age, anthropometric
and hemodynamic characteristics, and medications.
Vascular and Metabolic Disease
Our results parallel previous studies challenging the paradigm that type 2 DM normally precedes
and portends to a higher risk of developing vascular atherosclerosis [14,15], although they provide
direct evidence of this reverse temporal relation. Our results are consistent with findings in patients with
essential hypertension, in whom both resistant hypertension [8] and left ventricular hypertrophy [9]
precede the onset of type 2 DM. Our findings extend to patients with coronary artery disease (CAD), the
evidence of this reverse temporal relation. We hypothesize that a possible vicious circle might be at the
basis of this phenomenon. It is reasonable to speculate that the mechanisms relating atherosclerosis to
the later onset of DM might be related to insulin resistance, rather than directly to a hyperglycaemic state.
However, as the present study was not designed to explore the pathogenic mechanisms underlying
the association between SS and the development of diabetes, the insulin sensitivity in our study
population remained unexplored. Insulin resistance is a common pathogenic background for both DM
and atherosclerosis [16,17]. Insulin resistance plays a mechanistic role, along with other risk factors, in
the development of vascular damage and the occurrence of cardiovascular events (four) [18,19]. In
particular, insulin resistance-mediated endothelial dysfunction (an early step of atherosclerosis) [20]
has been proposed as a pathogenic mechanism of DM [21]. In turn, the presence of an extensive
vascular atherosclerosis might facilitate the onset and maintenance of the insulin resistance state.
This vicious circle can well explain how CV damage, instead of being a consequence, could progress,
together with the development of DM.
Our results cannot exclude the possibility that sub-clinical DM was already present at the time
of the index CA in patients who clinically manifested the disease during follow-up. As matter of
fact, endothelial dysfunction precedes and predicts incident diabetes, supporting the hypothesis that
vascular disease might precede pancreatic beta-cell failure, determining the shift from insulin resistance
to diabetes [22]. Moreover, endothelial dysfunction and impaired nitric oxide-mediated vasodilatation
have also been suggested to directly lead to reduced insulin delivery to skeletal muscles, resulting in
peripheral insulin resistance and hyper-glycaemia [23].
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It is of note that patients with medium or high SS manifested type 2 DM after a subclinical phase of
nearly four years from the index CA. As SS was evaluated cross-sectionally, this study does not clarify
whether the association between the magnitude of coronary atherosclerosis and the development of
type 2 DM is a time-dependent or atherosclerotic-dependent phenomenon. However, the latter seems
to play an important role, considering that the rate of DM increases with increasing the SS category
(Figure 1).
The evidence that patients with more than a low SS have a much higher risk of incident type 2 DM is
of clinical importance. It implies that these patients, in addition to their regular cardiovascular follow-up,
require tailored management in terms of metabolic risk, including attention to pharmacological therapy.
In particular, it has been demonstrated that a high-dose regimen with statins was associated with an
increased risk of new-onset DM [24,25]. In keeping with these findings, we found that statin intake
was significantly associated with more complex coronary artery disease, and was predictive of an
increased rate of DM.
In terms of the choice of revascularization strategies, the knowledge of the higher risk of
development of type 2 diabetes in patients with more than a low SS might favor surgical over
percutaneous interventions, after taking into account the anatomical features of the CAD and the
clinical conditions of the patient [26].
5. Conclusions
Our study demonstrates that the extension and severity of coronary atherosclerosis is a strong
predictor of development of type 2 DM. This finding advocates the need for developing dedicated
management strategies in patients with severe coronary artery disease, taking into account the risk of
late metabolic impairment following the index coronary intervention.
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